Cabozantinib,Atezolizumab
Roche,exelixis,
['pdl']
#asco22 slightly more efficacy in pdl1 positive cohort but big concern here is safety. diarrhea in 44-52% of patients and while few g3+, grade 2 diarrhea for a medicine taken daily is clinically very significant. phase iii study of this combo already ongoing (contact-01) 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him